2024
App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine—(TRACE)
Dörner L, Grosse L, Stange F, Hille H, Kurz S, Becker H, Volkmer S, Hippler M, Rieger D, Bombach P, Rieger J, Weinert L, Svensson L, Anders C, Cekin S, Paulsen F, Öner Ö, Ruhm K, Malek H, Möller Y, Tatagiba M, Wallwiener M, Eckert N, Escher P, Pfeifer N, Forschner A, Bauer A, Zips D, Bitzer M, Malek N, Gani C, Tabatabai G, Renovanz M. App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine—(TRACE). Neuro-Oncology Practice 2024, 11: 336-346. PMID: 38737615, PMCID: PMC11085831, DOI: 10.1093/nop/npae002.Peer-Reviewed Original ResearchHealth care professionalsHealth-related quality of lifePatient-reported outcomesAssessment of patient-reported outcomesQuality of lifePRO assessmentSystematic assessment of patient-reported outcomesAssessment of health-related quality of lifeElectronic PRO assessmentMedian distress scoreMayring's qualitative content analysisApp-based assessmentsEORTC QLQ-C30 instrumentHealth-related qualityBurden of symptomsPilot studyQualitative content analysisGlobal health scoreQLQ-C30 instrumentSmartphone applicationNeuro-oncology patientsSemi-structured interviewsInterdisciplinary expert panelCare professionalsPatient perspective
2023
Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system
Renovanz M, Kurz S, Rieger J, Walter B, Becker H, Hille H, Bombach P, Rieger D, Grosse L, Häusser L, Skardelly M, Merk D, Paulsen F, Hoffmann E, Gani C, Neumann M, Beschorner R, Rieß O, Roggia C, Schroeder C, Ossowski S, Armeanu-Ebinger S, Gschwind A, Biskup S, Schulze M, Fend F, Singer S, Zender L, Lengerke C, Brucker S, Engler T, Forschner A, Stenzl A, Kohlbacher O, Nahnsen S, Gabernet G, Fillinger S, Bender B, Ernemann U, Öner Ö, Beha J, Malek H, Möller Y, Ruhm K, Tatagiba M, Schittenhelm J, Bitzer M, Malek N, Zips D, Tabatabai G. Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system. Neuro-Oncology Advances 2023, 5: vdad012. PMID: 36915613, PMCID: PMC10007909, DOI: 10.1093/noajnl/vdad012.Peer-Reviewed Original ResearchBiomarker-guided therapyAdult patientsMolecular profilingNeuro-oncology patientsAdvanced tumorsClinical utilityTargeted therapyNervous systemClinical trialsTherapy recommendationsComprehensive molecular profilingInclusion of patientsData cutoffClinical benefitClinical outcomesTumorTherapyPatientsEvidence levelClinical careTrialsMtbTranslation studiesInvestigate feasibility
2020
Clinical neuro-oncology for the neurologist.
Lukas R, Taylor J, Kurz S, Mohile N. Clinical neuro-oncology for the neurologist. Neurology Clinical Practice 2020, 10: 458-465. PMID: 33299675, PMCID: PMC7717629, DOI: 10.1212/cpj.0000000000000765.Peer-Reviewed Original ResearchNeuro-oncologyReclassification of tumorsClinical neuro-oncologyClinical practiceClinically relevant pointsCNS lymphomaNeuro-oncology patientsBrain metastasesInfiltrating gliomasBrain tumorsStandard managementAdult neurologistsTumorPatient carePatientsMolecular characteristicsEvolving fieldNeurologistsBrainLymphomaMetastasisMeningiomasGliomaCNSClinic